Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...

The antithrombin assay will support dosing Qfitlia, the sixth Alnylam-discovered RNAi medicine to receive FDA approval.

Researchers at ACC suggested stratifying by age and TTR variant, plus cascade testing, could help identify those likely to ...

AI tools that analyze echocardiograms and electrocardiograms can identify those at higher risk of heart disease-related death, a study at the ACC meeting showed.

Researchers at the American College of Cardiology's annual meeting used proteomic approaches to uncover dysregulated signaling pathways in the disease.

BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...

The committee based its decision on data showing the subcutaneous formulation of Opdivo was not inferior to the intravenous formulation.

With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...

AI models trained on optical coherence tomography scans to detect eye diseases are showing promise in diagnosing heart ...

NEW YORK – The US Food and Drug Administration on Friday expanded the indication for Novartis' radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for use prior to chemotherapy in ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Thursday recommended against marketing authorization for Eli Llilly's Alzheimer's drug Kisunla ...